Roche: Oddo still a buyer; maintains target price
(CercleFinance.com) - After the US approval of Perjeta in breast cancer, in a three-year study, the invasive disease-free survival (iDFS) criterion, which measures the risk of a relapse in the disease or death, showed a difference of approximately 2% between both treatment arms.
These 2 percentage points (which may seem low) mean that 2 out of 100 women living much longer (sometimes several decades).
For this new indication, the broker expects potential additional revenues of 2 billion Swiss francs for Perjeta.
In all Oddo expects sales to peak at about 5 billion Swiss francs for Perjeta (all indications) by 2023.
This indication will therefore be a growth driver for Roche in 2018, along with Tecentriq, Hemlibra and Ocrevus.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.